LCT 0.02 Last updated EOD 21st October 2019
The following fact sheets provide a summary of our current business and research pipeline.
LCT actively protects a range of intellectual property consisting in our core transplantation and encapsulation technologies, our indication specific therapeutics and the use of designated pathogen free cells from a herd of Auckland Island pigs.
Our patents are grouped into series by the technology they apply to. We currently hold patents in a number of series across several jurisdictions including United States, Europe, New Zealand, Australia, Mexico, Singapore, South Africa and Russia.
LCT also has registered trademarks relating to LCT, NTCELL® and IMMUPEL™.
Our IP lawyers are AJ Park.